SEMA4D and prostate cancer: PlexinB1 and its ligands, Sema4D and Sema3C, are associated with tumor progression and bad prognosis of many tumor types [17], including breast [18,19], ovarian [19,20], glioma [21], and melanoma [22] as well as prostate cancer [10,23,24].